Repeat pull from proven relationships plus room left

Pfizer Inc. (PFE) — this company's answers

The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes existing customers/partners taking more on their own initiative, and that these relationships remain lightly penetrated. Look for specific examples. In the transcript, management discusses several products. For example, Prevnar: In the U.S., adult market is largely exhausted, but pediatric is growing. However, that's about market share, not existing customers expanding. For Abrysvo, they talk about retail contracting for '24-'25 season, but that's future. For Nurtec, they mention growth in prescriptions, but that's not necessarily existing customers taking more. For Oxbryta, they mention U.S. performance up 30% over prior year, but that's overall sales, not necessarily existing accounts expanding. Look for specific language about existing relationships deepening. For instance, in the international markets, Alexandre de Germay talks about focusing on top markets and increasing diagnosis rates for Vyndaqel, but that's about market expansion, not existing customers. For Eliquis, they see untapped opportunity, but again, that's market-level. The question asks: "counterparties the company has ALREADY SERVED AND PROVEN ITSELF WITH — existing customers, accounts, partners, members, or programs — are CURRENTLY, ON THEIR OWN INITIATIVE, TAKING OR COMMITTING TO MEANINGFULLY MORE from the company than they previously did" and "these same relationships remain LIGHTLY PENETRATED". Look for examples like: existing customers increasing orders, expanding usage, etc. In the transcript, there is mention of Comirnaty contracts with European countries that advanced some orders from 2024 into 2023. That is an example of existing partners (countries) taking more earlier. But is that "on their own initiative"? They decided to advance orders. And is it lightly penetrated? The transcript says "we don't see major vaccination uptakes in the future year" and that the 2023-2024 campaign is the type of acceleration we will see. So that might be a one-time bulge? Actually, they say that the pattern is seasonal, and they expect similar levels. So not necessarily lightly penetrated. Another example: For Abrysvo, they talk about retail contracting for '24-'25 season, but that's future. For Velsipity, they talk about securing access, but that's early. For Oxbryta, they say "U.S. performance.

← Back to the full PFE analysis